Pimicotinib Improves Joint Function in Two-Year Study
Patients with tenosynovial giant cell tumors saw sustained relief in pain and mobility during the long-term clinical trial.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to provide sufficient long-term data for new medical treatments?
New two-year data from the Phase 3 MANEUVER study show that pimicotinib provides sustained improvements in joint function and pain for patients with tenosynovial giant cell tumors. The results, presented at the 2026 European Society for Medical Oncology Congress, support ongoing regulatory reviews of the drug.
Why it matters
Tenosynovial giant cell tumors cause debilitating pain and mobility issues, and these findings suggest that long-term treatment with pimicotinib may help maintain physical function. These results provide critical evidence as the U.S. Food and Drug Administration considers the therapy for potential approval.
In the Phase 3 MANEUVER study of 94 patients, 76.2% achieved an objective response per RECIST v1.1 criteria after two years of treatment. While these results show sustained clinical benefits, the trial is ongoing and researchers have not yet established outcomes beyond the 24-month mark.
The players
Merck KGaA
A German science and technology company that develops oncology therapies and reported 21.1 billion euros in 2025 sales.
U.S. Food and Drug Administration
The federal agency currently conducting a regulatory review to determine if pimicotinib will be approved for use in the United States.
The details
Pimicotinib is a targeted therapy designed to block the colony-stimulating factor 1 receptor, which plays a key role in the tumor microenvironment of tenosynovial giant cell tumors. By inhibiting this signaling pathway, the drug helps reduce the proliferation of the tumor cells that damage joint tissue. Patients in the study received a 50 mg dose, with most participants maintaining treatment over the two-year period with minimal discontinuations due to adverse events.
Timeline
December 2025: Pimicotinib received regulatory approval in China.
March 1, 2026: The data cutoff date for calculating the median treatment duration.
June 2026: Pimicotinib received regulatory approval in Canada.
October 26, 2026: Two-year follow-up results were officially announced.
Health Landscape
The MANEUVER study contributes to a shifting landscape in orthopedic oncology, where targeted therapies are increasingly replacing broader systemic treatments. This development aligns with recent international approvals of similar targeted agents for rare, non-malignant but locally aggressive tumors.
Patients currently managing tenosynovial giant cell tumors should consult their rheumatologist or oncologist about the potential availability of new targeted therapies. It is worth discussing with your doctor how ongoing clinical data may influence future treatment options for joint preservation.
The takeaway
The two-year data suggest that targeted therapy can effectively manage both pain and mobility in patients with this rare condition. Individuals should track symptoms like joint stiffness and decreased range of motion, and discuss emerging treatment guidelines with a specialist.
Further reading
For more on evolving research in this area, see our coverage of Cancer.
Live Poll
Do you trust pharmaceutical companies to provide sufficient long-term data for new medical treatments?
